EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Allogene Therapeutics's Enterprise Value is $164.34 Mil.
Allogene Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-198.12 Mil. Therefore, Allogene Therapeutics's EV-to-FCF for today is -0.83.
The historical rank and industry rank for Allogene Therapeutics's EV-to-FCF or its related term are showing as below:
ALLO'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.59 Med: -1.74 Max: 0.98
Current: -0.83
During the past 8 years, the highest EV-to-FCF of Allogene Therapeutics was 0.98. The lowest was -21.59. And the median was -1.74.
ALLO's EV-to-FCF is ranked worse than 100% of 380
companies
in the Biotechnology industry
Industry Median: 9.69
vs ALLO: -0.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allogene Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Allogene Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's EV-to-FCF falls into.
Allogene Therapeutics's current Enterprise Value is $164.34 Mil.
Allogene Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-198.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allogene Therapeutics's PE Ratio (TTM) for today is calculated as:
Allogene Therapeutics's share price for today is $1.51.
Allogene Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Allogene Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your 